Davita Inc Stock Price, News & Analysis

Medtronic and DaVita are launching a new independent company focused on kidney care technology to enhance treatment experiences and patient outcomes. This collaboration aims to leverage Medtronic's healthcare technology skills and DaVita's expertise in kidney care to develop innovative products, including home-based dialysis solutions. Each company will hold equal stakes in the new entity, which will be governed by an independent management team. The transaction is expected to close within a year, pending regulatory approvals.

Medtronic and DaVita have announced a partnership to create a new independent kidney care-focused medical device company, NewCo. This joint venture aims to enhance kidney treatment and patient outcomes by leveraging Medtronic's healthcare technology and DaVita's expertise in kidney care. NewCo will develop innovative therapies and products, especially for home-based dialysis treatments, serving over three million kidney failure patients globally. Each company will have equal ownership and contribute financially to support NewCo's initial operations.

Dosis has rolled out its Smart Anemia Manager (SAM) at DaVita clinics nationwide, enhancing personalized dosing for erythropoiesis-stimulating agents (ESAs) used in treating chronic anemia in end-stage renal disease patients. This integration, which began in 2019, has influenced over 30 million dialysis treatments. CEO Shivrat Chhabra emphasized the importance of precision medicine in value-based care, aiming to improve patient outcomes while lowering healthcare costs through tailored dosing recommendations.

DaVita Inc. (NYSE: DVA) announced that its CFO, Joel Ackerman, will participate in a fireside chat with investors at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 11 a.m. EDT. Stakeholders can access the live webcast by registering on the Bank of America Securities page.

DaVita is a leading kidney care provider, serving 203,000 patients across 2,815 U.S. outpatient dialysis centers and 339 centers globally.

DaVita reported Q1 2022 financial results, highlighting a net income of $162 million, down from $237 million year-over-year. Diluted EPS was $1.61, a 10.1% decrease from the previous quarter, influenced by COVID-19 impacts and wage increases. Consolidated revenues reached $2.818 billion. Operating income fell to $338 million with a 12.0% margin. There was a decline in U.S. dialysis treatments by 2.2% from Q4 2021. DaVita continues to provide care to over 241,800 patients across 3,155 centers globally, despite opening nine new centers in Q1. The company also repurchased 2.1 million shares during this period.

DaVita Inc. (NYSE: DVA) will hold its quarterly conference call on May 5, 2022, at 5 p.m. EDT to discuss first quarter results. Results will be released after market close that same day. The call will be accessible via webcast on the DaVita Investor Relations webpage. DaVita is a leading kidney care provider, serving 203,000 patients at 2,815 outpatient dialysis centers in the U.S. and 339 centers across ten other countries. The company aims to enhance care quality globally.

Rockwell Medical (RMTI) announced a significant partnership expansion with DaVita (DVA), featuring a $7.5 million initial equity investment and an amended supply agreement. This collaboration aims to stabilize Rockwell's concentrates business, enabling profitable operation while ensuring reliable supply for dialysis treatment. The agreement includes a potential additional $7.5 million investment, contingent on meeting certain conditions. Rockwell Medical emphasizes its vital role in the dialysis sector, with ambitions to broaden its business through ongoing discussions with other key customers.